dc.contributor.author |
Cedó, Lídia |
dc.contributor.author |
García-León, Annabel |
dc.contributor.author |
Baila-Rueda, Lucía |
dc.contributor.author |
Santos, David |
dc.contributor.author |
Grijalva, Victor |
dc.contributor.author |
Martínez Cignoni, Melanie Raquel |
dc.contributor.author |
Carbó, José María |
dc.contributor.author |
Metso, Jari |
dc.contributor.author |
López Vilaró, Laura |
dc.contributor.author |
Zorzano Olarte, Antonio |
dc.contributor.author |
Valledor, Annabel F. |
dc.contributor.author |
Cenarro, Ana |
dc.contributor.author |
Jauhiainen, Matti |
dc.contributor.author |
Lerma Puertas, Enrique |
dc.contributor.author |
Fogelman, Alan M. |
dc.contributor.author |
Reddy, Srinivasa T. |
dc.contributor.author |
Escolà-Gil, Joan Carles |
dc.contributor.author |
Blanco Vaca, Francisco |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2016 |
dc.identifier |
https://ddd.uab.cat/record/203755 |
dc.identifier |
urn:10.1038/srep36387 |
dc.identifier |
urn:oai:ddd.uab.cat:203755 |
dc.identifier |
urn:pmid:27808249 |
dc.identifier |
urn:recercauab:ARE-85331 |
dc.identifier |
urn:scopus_id:84994275513 |
dc.identifier |
urn:articleid:20452322v6p36387 |
dc.identifier |
urn:wos_id:000386981400001 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/e52bdda6-7c48-41aa-aed1-7b2fa4233354 |
dc.identifier |
urn:pmc-uid:5093413 |
dc.identifier |
urn:pmcid:PMC5093413 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5093413 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Instituto de Salud Carlos III PI11/01076 |
dc.relation |
Instituto de Salud Carlos III PI12/00291 |
dc.relation |
Instituto de Salud Carlos III PI13/02507 |
dc.relation |
Instituto de Salud Carlos III RD12-0042-0055 |
dc.relation |
Ministerio de Economía y Competitividad SAF2011-23402 |
dc.relation |
Scientific reports ; Vol. 6 (November 2016), art. 36387 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Animals |
dc.subject |
Antineoplastic Agents |
dc.subject |
Apolipoprotein A-I |
dc.subject |
Breast Neoplasms |
dc.subject |
Cell Proliferation |
dc.subject |
Cell Survival |
dc.subject |
Female |
dc.subject |
Humans |
dc.subject |
Lipoproteins, LDL |
dc.subject |
MCF-7 Cells |
dc.subject |
Mice |
dc.subject |
Mice, Transgenic |
dc.subject |
Molecular Mimicry |
dc.subject |
Peptides |
dc.subject |
Xenograft Model Antitumor Assays |
dc.title |
ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer |
dc.type |
Article |
dc.description.abstract |
Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. We aimed to determine the effects of human apoA-I overexpression and administration of specific apoA-I mimetic peptide (D-4F) on tumour progression by using mammary tumour virus-polyoma middle T-antigen transgenic (PyMT) mice as a model of inherited breast cancer. Expression of human apoA-I in the mice did not affect tumour onset and growth in PyMT transgenic mice, despite an increase in the HDLc level. In contrast, D-4F treatment significantly increased tumour latency and inhibited the development of tumours. The effects of D-4F on tumour development were independent of 27-hydroxycholesterol. However, D-4F treatment reduced the plasma oxidized low-density lipoprotein (oxLDL) levels in mice and prevented oxLDL-mediated proliferative response in human breast adenocarcinoma MCF-7 cells. In conclusion, our study shows that D-4F, but not apoA-I-containing HDL, hinders tumour growth in mice with inherited breast cancer in association with a higher protection against LDL oxidative modification. |